Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Sponsor
Hunan Province Tumor Hospital
Study ID
NCT03647592
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.

Key Dates

First listed
Aug 27, 2018
Start date
Jun 1, 2018
Status verified
Dec 2023
Primary completion
Aug 31, 2024
Completion
Dec 1, 2025

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Cohorts 1
    patients with EGFR mutation-positive who received treatment of Erlotinib/Gefitinib Combined With Bevacizumab

Primary Outcome Measure

PFS [ Time Frame: Approximately 1 years ]

Central Contacts

Related Studies